A Combination Study of Flotetuzumab and MGA012 (an anti-PD-1 monoclonal antibody) in Patients with Acute Myeloid-Leukaemia (AML)
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Flotetuzumab (Primary) ; INCMGA 0012 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors MacroGenics
- 10 Dec 2019 Trial design released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 06 Nov 2019 According to an MacroGenics media release, the company has recently initiated this combination clinical study .
- 06 Nov 2019 Status changed from planning to recruiting, according to an MacroGenics media release.